Spleen Tyrosine Kinase phosphorylates VE-cadherin to cause endothelial barrier disruption in acute lung injury
Journal of Biological Chemistry · 2023-12 · 299 (12) · 105408
DOI: 10.1016/j.jbc.2023.105408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023-12. Verfasst von Mohammad Shadab und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Lung Biology and Disease Program, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Hauptthemen laut MEDLINE: Acute Lung Injury, Antigens, CD, Cadherins, Respiratory Distress Syndrome. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Increased endothelial cell (EC) permeability is a cardinal feature of acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Tyrosine phosphorylation of VE-cadherin is a key determinant of EC barrier disruption. However, the identity and role of tyrosine kinases in this context are incompletely understood. Here we report that Spleen Tyrosine Kinase (Syk) is a key mediator of EC barrier disruption and lung vascular leak in sepsis. Inhibition of Syk by pharmacological or genetic approaches, each reduced thrombin-induced EC permeability. Mechanistically, Syk associates with and phosphorylates VE-cadherin to cause EC permeability. To study the causal role of endothelial Syk in sepsis-induced ALI, we used a remarkably efficient and cost-effective approach based on gene transfer to generate EC-ablated Syk mice. These mice were protected against sepsis-induced loss of VE-cadherin and inflammatory lung injury. Notably, the administration of Syk inhibitor R788 (fostamatinib); currently in phase II clinical trial for the treatment of COVID-19, mitigated lung injury and mortality in mice with sepsis. These data identify Syk as a novel kinase for VE-cadherin and a druggable target against ALI in sepsis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Lung Biology and Disease Program, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
- Department of Medicine, Lung Biology and Disease Program, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
- Department of Pediatrics, Lung Biology and Disease Program, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: Arshad_Rahman@URMC.Rochester.edu.
Förderung
- NHLBI NIH HHS
- NIEHS NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute of General Medical Sciences
- Rockefeller University
Zitieren
APA
Shadab, M., Slavin, S. A., Mahamed, Z., Millar, M. W., Najar, R. A., Leonard, A., Pietropaoli, A., Dean, D. A., Fazal, F., & Rahman, A. (2023). Spleen Tyrosine Kinase phosphorylates VE-cadherin to cause endothelial barrier disruption in acute lung injury. Journal of Biological Chemistry, 299(12), 105408. https://doi.org/10.1016/j.jbc.2023.105408
Vancouver
Shadab M, Slavin SA, Mahamed Z, Millar MW, Najar RA, Leonard A, et al. Spleen Tyrosine Kinase phosphorylates VE-cadherin to cause endothelial barrier disruption in acute lung injury. Journal of Biological Chemistry. 2023;299(12):105408. doi:10.1016/j.jbc.2023.105408
BibTeX
@article{Shadab2023,
author = {Shadab, Mohammad and Slavin, Spencer A and Mahamed, Zahra and Millar, Michelle W and Najar, Rauf A and Leonard, Antony and Pietropaoli, Anthony and Dean, David A and Fazal, Fabeha and Rahman, Arshad},
title = {Spleen Tyrosine Kinase phosphorylates VE-cadherin to cause endothelial barrier disruption in acute lung injury},
journal = {Journal of Biological Chemistry},
year = {2023},
volume = {299},
number = {12},
pages = {105408},
doi = {10.1016/j.jbc.2023.105408}
}
EUVIMED